EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate

Benzinga10-08

On Tuesday, Oragenics Inc. (NYSE:OGEN) said it has completed a key study for its new concussion drug, ONP-002. What Happened: A recent study shows that the drug successfully targets areas inside the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473424033?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ejYN7aQcscir0UXBMKQacg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0465c7702528efeb9d4fec3695ea2096","is_english":true,"pubTime":"2024-10-08 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2473424033","market":"us","top_or_hot":-1,"title":"EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate","media":"Benzinga","content":"<div>\n<p>On Tuesday, Oragenics Inc. (NYSE:OGEN) said it has completed a key study for its new concussion drug, ONP-002.\nWhat Happened: A recent study shows that the drug successfully targets areas inside the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-oragenics-completes-key-fda-123021510.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/exclusive-oragenics-completes-key-fda-123021510.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Tuesday, Oragenics Inc. (NYSE:OGEN) said it has completed a key study for its new concussion drug, ONP-002.\nWhat Happened: A recent study shows that the drug successfully targets areas inside the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-oragenics-completes-key-fda-123021510.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OGEN","symbol_name":"Oragenics Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/exclusive-oragenics-completes-key-fda-123021510.html","article_id":"2473424033","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ejYN7aQcscir0UXBMKQacg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0465c7702528efeb9d4fec3695ea2096"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473424033","pubTimestamp":1728390621,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Tuesday, Oragenics Inc.  said it has completed a key study for its new concussion drug, ONP-002.What Happened: A recent study shows that the drug successfully targets areas inside the nose connected to the brain, making the drug more likely to reach and treat the brain after a concussion.In the study, ONP-002 was tested using a nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside a cast metal anatomical model of the interior nose.“In preparing for our Phase 2 study, we wanted to study whether our nasal spray device would give ONP-002 an increased chance of reaching the brain quickly after a concussion. The study results are promising, as they show the drug targets areas in the nose directly linked to the brain. This should increase the chances of the drug being effective in treating concussion and reduces the likelihood of it being swallowed, which is another encouraging sign,” said Michael Redmond, President of Oragenics.In August, O","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OGEN":"Oragenics Inc.","BK4139":"生物科技"},"translate_title":"独家：Oragenics完成FDA认可的脑震荡候选药物关键研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGEN":1},"content_text":"On Tuesday, Oragenics Inc. (NYSE:OGEN) said it has completed a key study for its new concussion drug, ONP-002.\nWhat Happened: A recent study shows that the drug successfully targets areas inside the nose connected to the brain, making the drug more likely to reach and treat the brain after a concussion.\nIn the study, ONP-002 was tested using a nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside a cast metal anatomical model of the interior nose.\nThe model is standard for intranasal drug delivery and is accepted by the FDA as a surrogate for the actual nasal passage.\nThe results showed that the drug spreads well in the nose areas, where it can be quickly absorbed into the brain.\nAlso Read: EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury.\nWhy It Matters: Oragenics is now preparing to move forward with human testing (Phase 2) in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug within 8 hours of the injury.\n“In preparing for our Phase 2 study, we wanted to study whether our nasal spray device would give ONP-002 an increased chance of reaching the brain quickly after a concussion. The study results are promising, as they show the drug targets areas in the nose directly linked to the brain. This should increase the chances of the drug being effective in treating concussion and reduces the likelihood of it being swallowed, which is another encouraging sign,” said Michael Redmond, President of Oragenics.\nIn August, Oragenics completed a study that indicates ONP-002 does not cause cardiotoxicity.\nA concussion is a mild traumatic brain injury that affects brain function, with an estimated 69 million cases reported annually worldwide.\nLong-term symptoms can develop in up to 20% of patients. Currently, there is no pharmaceutical treatment for concussions.\nPrice Action: OGEN stock closed at $0.39 on Monday.\nRead Next:\n\nReviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst\n\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nThis article EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473424033"}